Skip to content

rabbit anti-APP (Abeta-NT) polyclonal antibody 5729


Antibody summary

  • Rabbit polyclonal to APP (Abeta-NT)
  • Suitable for: ELISA,WB,IHC-P
  • Isotype: IgG
  • 100 µg
SKU: 5729parent Category: Tags: , ,
Weight1 lbs
Dimensions9 × 5 × 2 in







1 mg/mL





available sizes

100 µg

Available product – rabbit anti-APP (Abeta-NT) polyclonal antibody 5729

Tested applications
Recommended dilutions
Immunoblotting: use at 1:500-1:1,000 dilution.

Positive control: Mouse brain lysate.
Peptide corresponding to aa 653- 662 of human amyloid protein precursor (APP) or aa 1-10 of the 4kD Ab peptide generated by b- and g-secretases. The sequences are identical to those of rabbit, pig, cow, guinea pig, and chicken.
Size and concentration
100µg and lot specific
Storage Instructions
This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles.
Storage buffer
PBS, pH 7.4.
immunogen affinty purifcation
Compatible secondaries
goat anti-rabbit IgG, H&L chain specific, peroxidase conjugated, conjugated polyclonal antibody 9512
goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody 2079
goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody 7863
goat anti-rabbit IgG, H&L chain specific, Cross Absorbed polyclonal antibody 2371
goat anti-rabbit IgG, H&L chain specific, biotin conjugated polyclonal antibody, crossabsorbed 1715
goat anti-rabbit IgG, H&L chain specific, FITC conjugated polyclonal antibody, crossabsorbed 1720
Isotype control
Rabbit polyclonal - Isotype Control
target relevance
Protein names
Amyloid-beta precursor protein (APP) (ABPP) (APPI) (Alzheimer disease amyloid A4 protein homolog) (Alzheimer disease amyloid protein) (Amyloid precursor protein) (Amyloid-beta (A4) precursor protein) (Amyloid-beta A4 protein) (Cerebral vascular amyloid peptide) (CVAP) (PreA4) (Protease nexin-II) (PN-II) [Cleaved into: N-APP; Soluble APP-a
Gene names
Protein family
APP family
FUNCTION: Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis (PubMed:25122912). Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(o) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1 (By similarity). By acting as a kinesin I membrane receptor, plays a role in axonal anterograde transport of cargo towards synapses in axons (PubMed:17062754, PubMed:23011729). Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1. {ECO:0000250, ECO:0000250|UniProtKB:P12023, ECO:0000269|PubMed:17062754, ECO:0000269|PubMed:23011729, ECO:0000269|PubMed:25122912}.; FUNCTION: Amyloid-beta peptides are lipophilic metal chelators with metal-reducing activity. Bind transient metals such as copper, zinc and iron. In vitro, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), respectively. Amyloid-beta protein 42 is a more effective reductant than amyloid-beta protein 40. Amyloid-beta peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, inhibiting metal-catalyzed oxidation of lipoproteins. APP42-beta may activate mononuclear phagocytes in the brain and elicit inflammatory responses. Promotes both tau aggregation and TPK II-mediated phosphorylation. Interaction with overexpressed HADH2 leads to oxidative stress and neurotoxicity. Also binds GPC1 in lipid rafts.; FUNCTION: Appicans elicit adhesion of neural cells to the extracellular matrix and may regulate neurite outgrowth in the brain. {ECO:0000250}.; FUNCTION: The gamma-CTF peptides as well as the caspase-cleaved peptides, including C31, are potent enhancers of neuronal apoptosis.; FUNCTION: N-APP binds TNFRSF21 triggering caspase activation and degeneration of both neuronal cell bodies (via caspase-3) and axons (via caspase-6).
Subellular location
SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10383380, ECO:0000269|PubMed:20580937, ECO:0000269|PubMed:2649245, ECO:0000305|PubMed:25122912}; Single-pass type I membrane protein {ECO:0000269|PubMed:30630874, ECO:0000305|PubMed:10383380, ECO:0000305|PubMed:25122912}. Membrane {ECO:0000269|PubMed:2900137, ECO:0000305|PubMed:22584060}; Single-pass type I membrane protein {ECO:0000269|PubMed:2900137, ECO:0000269|PubMed:30630874, ECO:0000305|PubMed:22584060}. Perikaryon {ECO:0000269|PubMed:10341243}. Cell projection, growth cone {ECO:0000269|PubMed:10341243}. Membrane, clathrin-coated pit {ECO:0000269|PubMed:20580937}. Early endosome {ECO:0000269|PubMed:20580937}. Cytoplasmic vesicle {ECO:0000269|PubMed:20580937, ECO:0000269|PubMed:25122912}. Note=Cell surface protein that rapidly becomes internalized via clathrin-coated pits. Only a minor proportion is present at the cell membrane; most of the protein is present in intracellular vesicles (PubMed:20580937). During maturation, the immature APP (N-glycosylated in the endoplasmic reticulum) moves to the Golgi complex where complete maturation occurs (O-glycosylated and sulfated). After alpha-secretase cleavage, soluble APP is released into the extracellular space and the C-terminal is internalized to endosomes and lysosomes. Some APP accumulates in secretory transport vesicles leaving the late Golgi compartment and returns to the cell surface. APP sorts to the basolateral surface in epithelial cells. During neuronal differentiation, the Thr-743 phosphorylated form is located mainly in growth cones, moderately in neurites and sparingly in the cell body (PubMed:10341243). Casein kinase phosphorylation can occur either at the cell surface or within a post-Golgi compartment. Associates with GPC1 in perinuclear compartments. Colocalizes with SORL1 in a vesicular pattern in cytoplasm and perinuclear regions. {ECO:0000269|PubMed:10341243, ECO:0000269|PubMed:20580937}.; SUBCELLULAR LOCATION: [C83]: Endoplasmic reticulum {ECO:0000269|PubMed:14527950}. Golgi apparatus {ECO:0000269|PubMed:14527950}. Early endosome {ECO:0000269|PubMed:14527950}.; SUBCELLULAR LOCATION: [C99]: Early endosome {ECO:0000269|PubMed:14527950}.; SUBCELLULAR LOCATION: [Soluble APP-beta]: Secreted {ECO:0000269|PubMed:10656250, ECO:0000269|PubMed:2649245}.; SUBCELLULAR LOCATION: [Amyloid-beta protein 40]: Cell surface {ECO:0000269|PubMed:16154999}.; SUBCELLULAR LOCATION: [Amyloid-beta protein 42]: Cell surface {ECO:0000269|PubMed:11689470, ECO:0000269|PubMed:16154999}. Note=Associates with FPR2 at the cell surface and the complex is then rapidly internalized. {ECO:0000269|PubMed:11689470}.; SUBCELLULAR LOCATION: [Gamma-secretase C-terminal fragment 59]: Nucleus {ECO:0000269|PubMed:11544248}. Cytoplasm {ECO:0000269|PubMed:11544248}. Note=Located to both the cytoplasm and nuclei of neurons. It can be translocated to the nucleus through association with APBB1 (Fe65) (PubMed:11544248). In dopaminergic neurons, the phosphorylated Thr-743 form is localized to the nucleus (By similarity). {ECO:0000250|UniProtKB:P12023, ECO:0000269|PubMed:11544248}.
TISSUE SPECIFICITY: Expressed in the brain and in cerebrospinal fluid (at protein level) (PubMed:2649245). Expressed in all fetal tissues examined with highest levels in brain, kidney, heart and spleen. Weak expression in liver. In adult brain, highest expression found in the frontal lobe of the cortex and in the anterior perisylvian cortex-opercular gyri. Moderate expression in the cerebellar cortex, the posterior perisylvian cortex-opercular gyri and the temporal associated cortex. Weak expression found in the striate, extra-striate and motor cortices. Expressed in cerebrospinal fluid, and plasma. Isoform APP695 is the predominant form in neuronal tissue, isoform APP751 and isoform APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Appican is expressed in astrocytes. {ECO:0000269|PubMed:12859342, ECO:0000269|PubMed:1406936, ECO:0000269|PubMed:2649245}.
SUBUNIT: Binds, via its C-terminus, to the PID domain of several cytoplasmic proteins, including APBB family members, the APBA family, MAPK8IP1, SHC1 and, NUMB and DAB1 (By similarity). Binding to DAB1 inhibits its serine phosphorylation (By similarity). Interacts (via NPXY motif) with DAB2 (via PID domain); the interaction is impaired by tyrosine phosphorylation of the NPXY motif. Also interacts with GPCR-like protein BPP, APPBP1, IB1, KNS2 (via its TPR domains), APPBP2 (via BaSS) and DDB1. In vitro, it binds MAPT via the MT-binding domains (By similarity). Associates with microtubules in the presence of ATP and in a kinesin-dependent manner (By similarity). Interacts, through a C-terminal domain, with GNAO1. Amyloid-beta protein 42 binds CHRNA7 in hippocampal neurons. Amyloid-beta associates with HADH2. Soluble APP binds, via its N-terminal head, to FBLN1. Interacts with CPEB1 and AGER (By similarity). Interacts with ANKS1B and TNFRSF21. Interacts with ITM2B. Interacts with ITM2C. Interacts with IDE. Can form homodimers; dimerization is enhanced in the presence of Cu(2+) ions (PubMed:25122912). Can form homodimers; this is promoted by heparin binding. Amyloid-beta protein 40 interacts with S100A9. CTF-alpha product of APP interacts with GSAP. Isoform APP695 interacts with SORL1 (via N-terminal ectodomain); this interaction retains APP in the trans-Golgi network and reduces processing into soluble APP-alpha and amyloid-beta peptides (PubMed:16174740, PubMed:16407538, PubMed:17855360, PubMed:24523320). The C99 fragment also interacts with SORL1 (PubMed:16407538). Isoform APP751 interacts with SORL1 (PubMed:16174740). Isoform APP770 interacts with SORL1 (PubMed:16174740). Interacts with PLD3. Interacts with VDAC1 (PubMed:25168729). Interacts with NSG1; could regulate APP processing (By similarity). Amyloid-beta protein 42 interacts with FPR2 (PubMed:11689470). Interacts with SYT7 (By similarity). Interacts (via transmembrane region) with PSEN1; the interaction is direct (PubMed:30630874). Interacts with LRRK2 (PubMed:28720718). Interacts (via cytoplasmic domain) with KIF5B (PubMed:23011729). Interacts (via C-terminus) with APBB2/FE65L1 (via C-terminus) (PubMed:14527950, PubMed:8855266). Interacts (via intracellular domain) with APBB3 (PubMed:10081969). {ECO:0000250|UniProtKB:P08592, ECO:0000250|UniProtKB:P12023, ECO:0000269|PubMed:10081969, ECO:0000269|PubMed:10681545, ECO:0000269|PubMed:10816430, ECO:0000269|PubMed:11238726, ECO:0000269|PubMed:11278849, ECO:0000269|PubMed:11438549, ECO:0000269|PubMed:11517218, ECO:0000269|PubMed:11544248, ECO:0000269|PubMed:11689470, ECO:0000269|PubMed:11724784, ECO:0000269|PubMed:11877420, ECO:0000269|PubMed:11943163, ECO:0000269|PubMed:14527950, ECO:0000269|PubMed:15347684, ECO:0000269|PubMed:16174740, ECO:0000269|PubMed:16407538, ECO:0000269|PubMed:17051221, ECO:0000269|PubMed:17855360, ECO:0000269|PubMed:17895381, ECO:0000269|PubMed:18468999, ECO:0000269|PubMed:19225519, ECO:0000269|PubMed:19366692, ECO:0000269|PubMed:19901339, ECO:0000269|PubMed:20212142, ECO:0000269|PubMed:20811458, ECO:0000269|PubMed:22457725, ECO:0000269|PubMed:23011729, ECO:0000269|PubMed:24336208, ECO:0000269|PubMed:24523320, ECO:0000269|PubMed:25122912, ECO:0000269|PubMed:25168729, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:30630874, ECO:0000269|PubMed:8446172, ECO:0000269|PubMed:8626687, ECO:0000269|PubMed:8855266, ECO:0000269|PubMed:8887653, ECO:0000269|PubMed:9300481, ECO:0000269|PubMed:9338779, ECO:0000269|PubMed:9843960, ECO:0000269|PubMed:9890987}.
Post-translational modification
PTM: Proteolytically processed under normal cellular conditions. Cleavage either by alpha-secretase, beta-secretase or theta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, and the retention of corresponding membrane-anchored C-terminal fragments, C80, C83 and C99. Subsequent processing of C80 and C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is non-amyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid-beta proteins, amyloid-beta protein 40 and amyloid-beta protein 42, major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59). PSEN1 cleavage is more efficient with C83 than with C99 as substrate (in vitro) (PubMed:30630874). Amyloid-beta protein 40 and Amyloid-beta protein 42 are cleaved by ACE (PubMed:11604391, PubMed:16154999). Many other minor amyloid-beta peptides, amyloid-beta 1-X peptides, are found in cerebral spinal fluid (CSF) including the amyloid-beta X-15 peptides, produced from the cleavage by alpha-secretase and all terminating at Gln-686. {ECO:0000269|PubMed:10656250, ECO:0000269|PubMed:11604391, ECO:0000269|PubMed:16154999, ECO:0000269|PubMed:30630874}.; PTM: Proteolytically cleaved by caspases during neuronal apoptosis. Cleavage at Asp-739 by either CASP6, CASP8 or CASP9 results in the production of the neurotoxic C31 peptide and the increased production of amyloid-beta peptides. {ECO:0000269|PubMed:10319819}.; PTM: N-glycosylated (PubMed:2900137). N- and O-glycosylated (PubMed:2649245). O-glycosylation on Ser and Thr residues with core 1 or possibly core 8 glycans. Partial tyrosine glycosylation (Tyr-681) is found on some minor, short amyloid-beta peptides (amyloid-beta 1-15, 1-16, 1-17, 1-18, 1-19 and 1-20) but not found on amyloid-beta protein 38, amyloid-beta protein 40 nor on amyloid-beta protein 42. Modification on a tyrosine is unusual and is more prevelant in AD patients. Glycans had Neu5AcHex(Neu5Ac)HexNAc-O-Tyr, Neu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr and O-AcNeu5AcNeu5AcHex(Neu5Ac)HexNAc-O-Tyr structures, where O-Ac is O-acetylation of Neu5Ac. Neu5AcNeu5Ac is most likely Neu5Ac 2,8Neu5Ac linked. O-glycosylations in the vicinity of the cleavage sites may influence the proteolytic processing. Appicans are L-APP isoforms with O-linked chondroitin sulfate. {ECO:0000269|PubMed:16335952, ECO:0000269|PubMed:21712440, ECO:0000269|PubMed:22576872, ECO:0000269|PubMed:2649245, ECO:0000269|PubMed:2900137}.; PTM: Phosphorylation in the C-terminal on tyrosine, threonine and serine residues is neuron-specific (PubMed:10341243). Phosphorylation can affect APP processing, neuronal differentiation and interaction with other proteins (PubMed:10341243). Phosphorylated on Thr-743 in neuronal cells by Cdc5 kinase and Mapk10, in dividing cells by Cdc2 kinase in a cell-cycle dependent manner with maximal levels at the G2/M phase and, in vitro, by GSK-3-beta (PubMed:8131745, PubMed:11146006). The Thr-743 phosphorylated form causes a conformational change which reduces binding of Fe65 family members (PubMed:11517218). In dopaminergic (DA) neurons, phosphorylation on Thr-743 by LRKK2 promotes the production and the nuclear translocation of the APP intracellular domain (AICD) which induces DA neuron apoptosis (PubMed:28720718). Phosphorylation on Tyr-757 is required for SHC binding (PubMed:11877420). Phosphorylated in the extracellular domain by casein kinases on both soluble and membrane-bound APP. This phosphorylation is inhibited by heparin (PubMed:8999878). {ECO:0000269|PubMed:10341243, ECO:0000269|PubMed:11146006, ECO:0000269|PubMed:11517218, ECO:0000269|PubMed:11877420, ECO:0000269|PubMed:28720718, ECO:0000269|PubMed:8131745, ECO:0000269|PubMed:8999878}.; PTM: Extracellular binding and reduction of copper, results in a corresponding oxidation of Cys-144 and Cys-158, and the formation of a disulfide bond. In vitro, the APP-Cu(+) complex in the presence of hydrogen peroxide results in an increased production of amyloid-beta-containing peptides.; PTM: Trophic-factor deprivation triggers the cleavage of surface APP by beta-secretase to release sAPP-beta which is further cleaved to release an N-terminal fragment of APP (N-APP).; PTM: Amyloid-beta peptides are degraded by IDE. {ECO:0000250|UniProtKB:P12023}.; PTM: Sulfated on tyrosine residues. {ECO:0000269|PubMed:2649245}.
Target Relevance information above includes information from UniProt accession : P05067
The UniProt Consortium


Western blot analysis of APP in (A) human, (B) mouse, and (C) rat brain tissue lysates with APP antibody at 1 µg/mL.
Immunohistochemistry of APP in human brain (Alzheimer?s disease) tissue with APP antibody at 10 µg/mL.
Immunohistochemistry of APP in human brain tissue with APP antibody at 2.5 µg/mL.
Immunofluorescence of ASAH1 in rat heart tissue with ASAH1 antibody at 20 µg/mL. Green: APP Antibody (5729)
Blue: DAPI staining


Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.



relevant to this product
Western blot


No results found


There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.